Pluripotent stem cell for treating diabetic skin ulcer

Abstract

The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.

1 . A cell preparation for preventing and/or treating skin ulcer, comprising pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. 
     
     
         2 . The cell preparation according to  claim 1 , comprising a cell fraction wherein pluripotent stem cells positive for SSEA-3 have been concentrated by external stress stimulation. 
     
     
         3 . The cell preparation according to  claim 1  or  2 , wherein the skin ulcer is selected from the group consisting of diabetic skin ulcer, decubitus ulcer, venous stasis ulcer, arterial ulcer, radiation ulcer, necrotizing fasciitis and third degree burns. 
     
     
         4 . The cell preparation according to any one of  claims 1  to  3 , wherein the pluripotent stem cells are CD105-positive. 
     
     
         5 . The cell preparation according to any one of  claims 1  to  4 , wherein the pluripotent stem cells are CD117-negative and CD146-negative. 
     
     
         6 . The cell preparation according to any one of  claims 1  to  5 , wherein the pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative and CD271-negative. 
     
     
         7 . The cell preparation according to any one of  claims 1  to  6 , wherein the pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tryp1-negative and Dct-negative. 
     
     
         8 . The cell preparation according to any one of  claims 1  to  7 , wherein the pluripotent stem cells are pluripotent stem cells having all of the following properties:
 (i) low or absent telomerase activity; 
 (ii) ability to differentiate into cells of any of the three germ layers; 
 (iii) absence of demonstration of neoplastic proliferation; and 
 (iv) self-renewal ability. 
 
     
     
         9 . The cell preparation according to any one of  claims 1  to  8 , wherein the pluripotent stem cells have the ability to differentiate into one or more cells selected from the group consisting of epidermal keratinocytes, vascular endothelial cells, vascular pericytes, adipocytes, preadipocytes, skin fibroblasts and nerve sheath cells.